G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation

T. Seshadri, K. Al-Farsi, J. Stakiw, C. Ma, R. Saragosa, N. Franke, A. Keating, M. Crump, J. Kuruvilla

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Peripheral blood hematopoietic progenitor cells (PBHC) are the standard source of support for high-dose chemotherapy because of faster recovery of marrow function. Unfortunately, a proportion of patients are unable to mobilize adequate progenitors to proceed to autologous hematopoietic cell transplant (AHCT). Granulocyte-CSF-stimulated BM-derived hematopoietic progenitor cells (BMHC) may circumvent this problem. From 1999 to 2006, 52 patients (cases) with AML, Hodgkin (HL) or non-Hodgkin's lymphoma (NHL) in whom PBHC mobilization failed underwent a G-CSF-stimulated bone marrow harvest and proceeded to AHCT. Their outcome was compared with 422 patients (controls) with AML, HL and NHL undergoing AHCT using only PBHC. Twenty-three patients received BMHC alone and 29 patients recieved a combination of PBHC and BMHC. Median engraftment time for neutrophils (>0.5 × 109/l) and platelets (>20 × 109/l) were 14 and 27 days, but significantly longer when compared with controls (11days, 11 days, P<0.0001). Patients receiving both PBHC and BMHC had faster engraftment, when compared with those receiving BMHC alone (P<0.001). In conclusion, performing an AHCT using G-CSF-stimulated BMHC in patients failing PBHC collection is feasible with faster engraftment seen in patients receiving both BMHC and PBHC over BMHC alone.

Original languageEnglish
Pages (from-to)733-737
Number of pages5
JournalBone Marrow Transplantation
Volume42
Issue number11
DOIs
Publication statusPublished - 2008

Fingerprint

Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cells
Stem Cells
Transplantation
Transplants
Non-Hodgkin's Lymphoma
Bone Marrow
Recovery of Function
Hodgkin Disease
Granulocytes
Neutrophils

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation. / Seshadri, T.; Al-Farsi, K.; Stakiw, J.; Ma, C.; Saragosa, R.; Franke, N.; Keating, A.; Crump, M.; Kuruvilla, J.

In: Bone Marrow Transplantation, Vol. 42, No. 11, 2008, p. 733-737.

Research output: Contribution to journalArticle

Seshadri, T. ; Al-Farsi, K. ; Stakiw, J. ; Ma, C. ; Saragosa, R. ; Franke, N. ; Keating, A. ; Crump, M. ; Kuruvilla, J. / G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation. In: Bone Marrow Transplantation. 2008 ; Vol. 42, No. 11. pp. 733-737.
@article{305dfda62c33430f8fe823dd30ea58bd,
title = "G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation",
abstract = "Peripheral blood hematopoietic progenitor cells (PBHC) are the standard source of support for high-dose chemotherapy because of faster recovery of marrow function. Unfortunately, a proportion of patients are unable to mobilize adequate progenitors to proceed to autologous hematopoietic cell transplant (AHCT). Granulocyte-CSF-stimulated BM-derived hematopoietic progenitor cells (BMHC) may circumvent this problem. From 1999 to 2006, 52 patients (cases) with AML, Hodgkin (HL) or non-Hodgkin's lymphoma (NHL) in whom PBHC mobilization failed underwent a G-CSF-stimulated bone marrow harvest and proceeded to AHCT. Their outcome was compared with 422 patients (controls) with AML, HL and NHL undergoing AHCT using only PBHC. Twenty-three patients received BMHC alone and 29 patients recieved a combination of PBHC and BMHC. Median engraftment time for neutrophils (>0.5 × 109/l) and platelets (>20 × 109/l) were 14 and 27 days, but significantly longer when compared with controls (11days, 11 days, P<0.0001). Patients receiving both PBHC and BMHC had faster engraftment, when compared with those receiving BMHC alone (P<0.001). In conclusion, performing an AHCT using G-CSF-stimulated BMHC in patients failing PBHC collection is feasible with faster engraftment seen in patients receiving both BMHC and PBHC over BMHC alone.",
author = "T. Seshadri and K. Al-Farsi and J. Stakiw and C. Ma and R. Saragosa and N. Franke and A. Keating and M. Crump and J. Kuruvilla",
year = "2008",
doi = "10.1038/bmt.2008.249",
language = "English",
volume = "42",
pages = "733--737",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation

AU - Seshadri, T.

AU - Al-Farsi, K.

AU - Stakiw, J.

AU - Ma, C.

AU - Saragosa, R.

AU - Franke, N.

AU - Keating, A.

AU - Crump, M.

AU - Kuruvilla, J.

PY - 2008

Y1 - 2008

N2 - Peripheral blood hematopoietic progenitor cells (PBHC) are the standard source of support for high-dose chemotherapy because of faster recovery of marrow function. Unfortunately, a proportion of patients are unable to mobilize adequate progenitors to proceed to autologous hematopoietic cell transplant (AHCT). Granulocyte-CSF-stimulated BM-derived hematopoietic progenitor cells (BMHC) may circumvent this problem. From 1999 to 2006, 52 patients (cases) with AML, Hodgkin (HL) or non-Hodgkin's lymphoma (NHL) in whom PBHC mobilization failed underwent a G-CSF-stimulated bone marrow harvest and proceeded to AHCT. Their outcome was compared with 422 patients (controls) with AML, HL and NHL undergoing AHCT using only PBHC. Twenty-three patients received BMHC alone and 29 patients recieved a combination of PBHC and BMHC. Median engraftment time for neutrophils (>0.5 × 109/l) and platelets (>20 × 109/l) were 14 and 27 days, but significantly longer when compared with controls (11days, 11 days, P<0.0001). Patients receiving both PBHC and BMHC had faster engraftment, when compared with those receiving BMHC alone (P<0.001). In conclusion, performing an AHCT using G-CSF-stimulated BMHC in patients failing PBHC collection is feasible with faster engraftment seen in patients receiving both BMHC and PBHC over BMHC alone.

AB - Peripheral blood hematopoietic progenitor cells (PBHC) are the standard source of support for high-dose chemotherapy because of faster recovery of marrow function. Unfortunately, a proportion of patients are unable to mobilize adequate progenitors to proceed to autologous hematopoietic cell transplant (AHCT). Granulocyte-CSF-stimulated BM-derived hematopoietic progenitor cells (BMHC) may circumvent this problem. From 1999 to 2006, 52 patients (cases) with AML, Hodgkin (HL) or non-Hodgkin's lymphoma (NHL) in whom PBHC mobilization failed underwent a G-CSF-stimulated bone marrow harvest and proceeded to AHCT. Their outcome was compared with 422 patients (controls) with AML, HL and NHL undergoing AHCT using only PBHC. Twenty-three patients received BMHC alone and 29 patients recieved a combination of PBHC and BMHC. Median engraftment time for neutrophils (>0.5 × 109/l) and platelets (>20 × 109/l) were 14 and 27 days, but significantly longer when compared with controls (11days, 11 days, P<0.0001). Patients receiving both PBHC and BMHC had faster engraftment, when compared with those receiving BMHC alone (P<0.001). In conclusion, performing an AHCT using G-CSF-stimulated BMHC in patients failing PBHC collection is feasible with faster engraftment seen in patients receiving both BMHC and PBHC over BMHC alone.

UR - http://www.scopus.com/inward/record.url?scp=58149473086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149473086&partnerID=8YFLogxK

U2 - 10.1038/bmt.2008.249

DO - 10.1038/bmt.2008.249

M3 - Article

VL - 42

SP - 733

EP - 737

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 11

ER -